The 长盛A100 (also known as the A100 vaccine) is a COVID19 vaccine developed by Changsheng Biotechnology, a Chinese biopharmaceutical company、Here's what I found:
Basic Information:
* Developer: Changsheng Biotechnology (also known as Changsheng Bio or Changsheng)
* Type: Inactivated whole virus vaccine (similar to Sinopharm's BBIBPCorV)
* Production: Produced in Beijing, China
Clinical Trials:
* Phase 1/2 trials: Conducted in China, showed promising results in terms of safety and immunogenicity.
* Phase 3 trials: Conducted in several countries, including China, Brazil, and Indonesia, with over 10,000 participants.
Efficacy and Safety:
* Efficacy: Reported to be around 9297% against severe COVID19 and 7080% against mild/moderate COVID19.
* Safety: Generally welltolerated, with common side effects being mild and transient (e.g., pain at injection site, fatigue).
Regulatory Approval:
* Emergency use approval: Granted in China in 2020.
* Full approval: Granted in China in 2021.
Global Distribution:
* Distributed in China, as well as exported to several countries, including Brazil, Indonesia, and others.
Comparison to Other Vaccines:
* Similarities with Sinopharm's BBIBPCorV, another inactivated whole virus vaccine.
* Comparable efficacy to other inactivated whole virus vaccines.
Keep in mind that information on vaccines can evolve rapidly, and I might not have the most uptodate information、If you're looking for the latest on the 长盛A100 vaccine, I recommend checking with reputable sources, such as the World Health Organization (WHO), the Chinese National Medical Products Administration (NMPA), or peerreviewed scientific journals.
Do you have any specific questions about the 长盛A100 vaccine or COVID19 vaccines in general?